IPH-5301 is under clinical development by Innate Pharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IPH-5301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IPH-5301 overview

IPH-5301 is under development for the treatment of solid tumors including human epidermal growth factor receptor 2 positive breast cancer (HER2+ breast cancer), gastric cancer, gastroesophageal (GE) junction carcinomas, ovarian cancer, esophageal cancer, endometrial cancer, lung cancer and pancreatic cancer. The drug candidate is a humanized effector-silent IgG1 monoclonal antibody that acts by targeting CD73, 5' Nucleotidase (Ecto 5' Nucleotidase). It is administered through parenteral route.

Innate Pharma overview

Innate Pharma is a biotechnology company that develops antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory (r/r) hairy cell leukemia. The company is investigating Lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody for cutaneous T-cell lymphoma (CTCL); Monalizumab, an immune checkpoint inhibitor targeting solid tumors, head and neck cancer, and Avdoralimab antibody against bullous pemphigoid. Innate Pharma is also evaluating IPH5201, IPH5301, IPH6101 and IPH62 antibodies for the treatment of various of tumors. It works in partnership with Sanofi SA, AstraZeneca Plc and other biopharmaceutical companies to develop its products. Innate Pharma is headquartered in Marseille, Provence Alpes Cote d’Azur, France.

For a complete picture of IPH-5301’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.